OnKure gets FDA nod to start clinical trials

BOULDER — OnKure Inc., a Boulder-based developer of cancer therapies, has been given the go-ahead by the U.S. Food and Drug Administration to begin phase one clinical trials for the company’s lead drug OKI-179.

“OnKure’s platform is capable of transforming naturally occurring, biologically active lead compounds into commercial drugs that address a variety of diseases, with an emphasis on helping patients suffering from cancer,” according to a company news release.

OnKure is collaborating with the University of Colorado’s Anschutz Cancer Center and the University of Texas’s Dell Medical School on the clinical trial.

“We are delighted that OKI-179 is poised to enter clinical development,” OnKure CEO Tony Piscopio said in a prepared statement. “We are excited to see how this potential best-in-class molecule will perform in carefully selected patient populations.”

BOULDER — OnKure Inc., a Boulder-based developer of cancer therapies, has been given the go-ahead by the U.S. Food and Drug Administration to begin phase one clinical trials for the company’s lead drug OKI-179.

“OnKure’s platform is capable of transforming naturally occurring, biologically active lead compounds into commercial drugs that address a variety of diseases, with an emphasis on helping patients suffering from cancer,” according to a company news release.

OnKure is collaborating with the University of Colorado’s Anschutz Cancer Center and the University of Texas’s Dell Medical School on the clinical trial.

“We are delighted that OKI-179 is poised to enter clinical development,” OnKure CEO Tony Piscopio said in a prepared statement. “We are excited to see how this potential best-in-class molecule will perform in carefully selected patient populations.”